Chris Ryan

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.

The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.

Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.

The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.

Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

Everett Meyer, MD, PhD, outlines ongoing research and the potential role for Orca-T in advanced hematologic malignancies.

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL.